Philogen SpA (IT:PHIL)
:PHIL
Want to see IT:PHIL full AI Analyst Report?
Top Page
Philogen SpA
(PHIL)
Select Model
Select Model
Rating:67Neutral
Price Target:
€24.50
▲(5.60% Upside)
Action:Downgraded
Date:04/13/26
Strong recent financial performance (high profitability, strong cash generation, and low leverage) supports the score, but it is meaningfully offset by weak technicals (below major moving averages with negative MACD) and uncertain valuation signals due to a negative P/E and no dividend yield data.
Positive Factors
Balance-sheet strength
Very conservative capitalization and a materially larger equity base give Philogen long-term financial flexibility. Low debt limits solvency risk during clinical cycles, supports continued R&D funding or partnering negotiations, and reduces likelihood of forced dilutive financing under normal adverse scenarios.
Negative Factors
Revenue volatility / lumpiness
The dramatic 2025 revenue jump appears episodic and likely reflects milestone or lump-sum events rather than steady product sales. Such lumpy receipts make forecasting, resource allocation and valuation of recurring profitability uncertain and can create large swings in reported earnings and cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Very conservative capitalization and a materially larger equity base give Philogen long-term financial flexibility. Low debt limits solvency risk during clinical cycles, supports continued R&D funding or partnering negotiations, and reduces likelihood of forced dilutive financing under normal adverse scenarios.
Read all positive factors
Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€662.35M
Dividend YieldN/A
Average Volume (3M)19.28K
Price to Earnings (P/E)58.8
Beta (1Y)-0.16
Revenue Growth324.79%
EPS Growth407.11%
CountryIT
Employees174
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)1.16
Shares Outstanding29,242,860
10 Day Avg. Volume19,753
30 Day Avg. Volume19,281
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.51
Price to Sales (P/S)2.99
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.00Price Target Upside12.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)€53.80M
Philogen SpA Business Overview & Revenue Model
Company Description
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma ...
How the Company Makes Money
Philogen’s revenue model is primarily driven by monetizing its drug-development and biologics platform through a mix of (i) collaboration and licensing-related income and (ii) funding tied to development work, alongside (iii) potential future comm...
Philogen SpA Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.86M | 314.32M | 74.00M | 23.13M | 23.71M | 2.50M |
| Gross Profit | 43.76M | 271.84M | 54.42M | 5.67M | 10.53M | -8.14M |
| EBITDA | 43.70M | 255.84M | 44.75M | -2.05M | -1.17M | -12.98M |
| Net Income | 45.91M | 229.68M | 45.29M | -6.16M | -5.38M | -15.72M |
Balance Sheet | ||||||
| Total Assets | 159.35M | 437.33M | 168.45M | 119.27M | 125.83M | 132.75M |
| Cash, Cash Equivalents and Short-Term Investments | 100.02M | 379.22M | 113.73M | 75.34M | 86.20M | 101.68M |
| Total Debt | 11.50M | 10.88M | 11.51M | 14.91M | 15.76M | 16.49M |
| Total Liabilities | 33.54M | 63.46M | 29.80M | 28.68M | 27.91M | 27.67M |
| Stockholders Equity | 125.81M | 373.86M | 138.66M | 90.59M | 97.92M | 105.09M |
Cash Flow | ||||||
| Free Cash Flow | 37.15M | 268.05M | 38.67M | -10.37M | -9.15M | -25.85M |
| Operating Cash Flow | 39.55M | 271.44M | 40.84M | -4.82M | -4.94M | -19.03M |
| Investing Cash Flow | -36.03M | -171.82M | -22.28M | 159.00K | 24.20M | -47.77M |
| Financing Cash Flow | -4.80M | -2.99M | -3.78M | -4.17M | -3.78M | 63.05M |
Philogen SpA Technical Analysis
Positive
23.20
Price Trends
21.44
Positive
21.24
Positive
21.92
Positive
Market Momentum
0.24
Positive
55.60
Neutral
61.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Positive. The current price of 23.2 is above the 20-day moving average (MA) of 22.63, above the 50-day MA of 21.44, and above the 200-day MA of 21.92, indicating a bullish trend. The MACD of 0.24 indicates Positive momentum. The RSI at 55.60 is Neutral, neither overbought nor oversold. The STOCH value of 61.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHIL.
Philogen SpA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | €10.48B | 21.98 | 21.26% | 2.67% | 9.87% | 13.63% | |
75 Outperform | €1.32B | 19.53 | 15.29% | 1.58% | 4.42% | -16.04% | |
67 Neutral | €662.35M | 58.78 | 45.54% | ― | 324.79% | 407.11% | |
67 Neutral | €3.59B | 19.06 | 12.16% | 1.80% | 0.81% | -15.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
41 Neutral | €9.75M | -0.02 | -51.46% | ― | 74.59% | ― |
* General Sector Average
IT:PHIL
Philogen SpA
22.65
-3.32
-12.77%
IT:DIA
DiaSorin S.p.A.
66.50
-25.75
-27.91%
IT:ELN
El.En. S.p.A.
16.46
5.94
56.43%
IT:FDA
Fidia Spa
0.01
-0.51
-97.69%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
50.80
-2.48
-4.65%
IT:ARBS
Arterra Bioscience SpA
2.83
0.64
29.40%
Philogen SpA Corporate Events
Philogen Publishes Shareholders’ Meeting Minutes and Highlights Targeted Cancer-Drug Focus
May 21, 2026
Philogen S.p.A., an Italian-Swiss biotechnology group, focuses on developing targeted anticancer therapies that use proprietary ligands, including monoclonal antibodies and small molecules, to deliver powerful agents directly to tumors while limit...
Philogen Maintains Strong Cash Position as Oncology Pipeline Advances on Schedule
May 12, 2026
Philogen reported a solid financial position for the first quarter of 2026, with a positive net financial position of €355.4 million and liquidity of €366.1 million, only slightly lower than year-end despite operating and financial exp...
Philogen Reports April On‑Market Share Purchases by Mediobanca
May 4, 2026
Philogen S.p.A. disclosed a series of share purchase transactions carried out on the Italian EXM market in April 2026 by Mediobanca S.p.A., acting under an “other engagement” mandate. Across multiple trading sessions between 8 and 23 A...
Philogen Approves 2025 Results, €0.70 Dividend and New Share Buyback Mandate
Apr 29, 2026
Philogen’s 2026 ordinary shareholders’ meeting approved the 2025 separate financial statements and directed the full-year net profit of €229.68 million, along with portions of retained earnings and share premium, into a non-distr...
Philogen Continues Euronext Milan Share Buyback, Nears 0.9% Treasury Stake
Apr 27, 2026
Philogen has continued to execute its share buyback programme on Euronext Milan, repurchasing 2,711 shares between 20 and 24 April 2026 at an average price of €20.9329, for a total outlay of €56,749.03. Since the programme’s laun...
Philogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting
Apr 20, 2026
Philogen S.p.A., the Italian-Swiss biotech group specializing in targeted anti-tumor therapies, has detailed the structure of its share capital ahead of its shareholders’ meeting scheduled for 29 April 2026. The company leverages proprietary...
Philogen Adds to Treasury Stock as Biotech Group Advances Targeted Cancer Strategy
Apr 20, 2026
Philogen S.p.A., the Italian-Swiss biotech group specializing in targeted anti-tumor therapies, continues to expand its proprietary pipeline by exploiting monoclonal antibodies and small molecules that home in on tumor-associated blood vessels. Th...
Philogen Expands Treasury Stock Position as Share Buyback Programme Progresses
Apr 13, 2026
Philogen has continued its share buyback programme on Euronext Milan, repurchasing 6,729 shares between 6 and 10 April 2026, equal to 0.0166% of its share capital, for a total outlay of about €136,600 at an average price of roughly €20...
Philogen Publishes 2025 Financial and Governance Reports Ahead of April 2026 Shareholders’ Meeting
Apr 8, 2026
Philogen S.p.A., a biotechnology group specializing in targeted anticancer therapies and other potential applications for severe diseases, leverages proprietary ligand-isolation technologies and a broad patent portfolio to develop drugs that conce...
Philogen Discloses March Share Purchases by Mediobanca on Italian Market
Apr 8, 2026
Philogen S.p.A. disclosed that Mediobanca S.p.A., acting under an unspecified engagement, carried out a series of share purchase transactions in Philogen stock on the Italian regulated market in early March 2026. Over the period from 2 to 6 March,...
Philogen Publishes Documentation Ahead of April 2026 Shareholders’ Meeting
Mar 30, 2026
Philogen S.p.A., an Italian-Swiss biotechnology group specializing in targeted anti-cancer therapies based on tumor and vascular targeting technologies, focuses on developing innovative pharmaceuticals for high-mortality diseases using proprietary...
Philogen posts record 2025 profit on RayzeBio deal, plans dividend and R&D push
Mar 27, 2026
Philogen reported record 2025 results, with net profit surging to €229.7 million and revenue from contracts with customers jumping more than fourfold to €314.3 million, largely driven by a major upfront payment from a licensing deal wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.